The 3rd Next-Generation Conjugates Summit is back!
The 3rd Next-Generation Conjugates Summit (Boston | February 26-28, 2024) is the only event dedicated to showcasing conjugate drugs with novel payloads and formats, providing unrivalled access to 30+ speakers discussing innovation and development in bispecific-drug conjugates, antibody-oligonucleotide conjugates, peptide-drug conjugates plus many other novel conjugates types.
This event serves as the ultimate hotbed of discussion and potential partnerships for 100+ leading novel conjugate developers to expand the toolkit of conjugate design and successfully progress your novel conjugates into the clinic – download the brochure here.
Here are some of our agenda highlights:
- Explore advancements in gaining successful therapeutic effects in non-oncology indications, from Duchenne muscular dystrophy to obesity and diabetes at our Non-Oncology Focus Day with Dyne Therapeutics, Regeneron, and Johnson & Johnson
- Survey the diverse scope of innovation in novel technology beyond traditional mAbs and payloads, including immune stimulating payloads, bispecific antibodies, and radiopharmaceuticals in our Discovery Stream with Almac Discovery, Elucida Oncology, Antikor and Dantari
- Uncover the most exciting clinical advancements from case-study-led plenary sessions to get one step ahead of your clinical development and improve chances of progression into the clinic and beyond with VincerX Pharma, Zymeworks, Clarity Pharmaceuticals and Dyne Therapeutics
- Share your thoughts and collaborate in our deep-dive workshop sessions to optimise the pairing of your novel format and target to guide your R&D and set up for success in your next-generation conjugate development with Eli Lilly & Co, Debiopharm, and Abzena
- Develop improved manufacturing and CMC strategies to prepare for your inevitable manufacturing processes to streamline your downstream development with Mersana and Radiopharm Theranostics
With recent high-profile collaborations including BMS expanding their partnership with Avidity Bioscience for their Antibody-Oligonucleotide, and Seagen and Nurix collaborating on a degrader-conjugate, next-generation conjugates are being thrust into the spotlight as the future of ADCs, so you can’t miss this one!
